CoChat
Sign Up
Cited by 28Bacteriophages and microbial interactionsAdvanced Drug Delivery SystemsNanoparticle-Based Drug Delivery

The DOI matches its Crossref record.

Enteric-coated bacteriophage tablets for oral administration against gastrointestinal infections

Khanal, Dipesh, Chang, Rachel Yoon Kyung, Hick, Christopher, Morales, Sandra, Chan, Hak-Kim·2021·International Journal of Pharmaceutics
DOI 10.1016/j.ijpharm.2021.121206
Open this paper in CoChat — free account

Abstract

Intestinal Pseudomonas aeruginosa is highly problematic in immunocompromised patients such as those in intensive care units in hospitals. Phage therapy is an attractive alternative or supplementary therapy to antibiotics as it not only kills multidrug-resistant bacteria, but also minimises the disruption of gut microflora. Solid oral dosage forms (i.e., tablets) have the potential to effectively deliver viable phages to the gastrointestinal tract, but formulation studies have been scarce. In this study, Pseudomonas-targeting phage PEV20 was used as a model to produce tablets suitable for oral delivery by utilising industry-scale tablet compression and tablet coating machines. Phage tablets were produced by (i) spray drying of phages, (ii) direct compression of the phage powders into tablets, and then (iii) tablet coating. The resulting phage tablets had negligible phage titre reduction throughout the process and passed the British Pharmacopeia tests, including friability, weight variation, disintegration and dissolution of the tablets as well as weight gain and disintegration (in 0.1 M HCl and pH 7.4 phosphate buffer) of coated tablets. The developed formulation method can be utilised to produce tablets containing other phages and phage cocktails that are effective against enteric bacterial infections.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2021.121206

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 35

  1. Abedon, 2011, Chapter 1 - Phage therapy pharmacology: calculating phage dosing, 1, 10.1016/B978-0-12-387044-5.00001-7 · DOI
  2. Anpilov, 1984, Preventive effectiveness of dried polyvalent Shigella bacteriophage in organized collective farms, Voen. Med. Zh., 5, 39
  3. Chang, 2018, Phage therapy for respiratory infections, Adv. Drug Deliv. Rev., 133, 76, 10.1016/j.addr.2018.08.001 · DOI
  4. Chang, 2018, Proof-of-principle study in a murine lung infection model of antipseudomonal activity of phage PEV20 in a dry-powder formulation, Antimicrob. Agents Chemother., 62, 10.1128/AAC.01714-17 · DOI
  5. Chang, 2019, Storage stability of inhalable phage powders containing lactose at ambient conditions, Int. J. Pharm., 560, 11, 10.1016/j.ijpharm.2019.01.050 · DOI
  6. Chang, 2020, Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization, Bioeng. Transl. Med., 5, 10.1002/btm2.10159 · DOI
  7. Chang, 2020, Overcoming challenges for development of amorphous powders for inhalation, Expert. Opin. Drug Deliv., 17, 1583, 10.1080/17425247.2020.1813105 · DOI
  8. Chang, 2021, Dry powder pharmaceutical biologics for inhalation therapy, Adv. Drug Deliv. Rev., 172, 64, 10.1016/j.addr.2021.02.017 · DOI
  9. Chang, 2021, Hydrogel formulations containing non-ionic polymers for topical delivery of bacteriophages, Int. J. Pharm., 605, 120850, 10.1016/j.ijpharm.2021.120850 · DOI
  10. Chang, 2017, Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection, Eur. J. Pharm. Biopharm., 121, 1, 10.1016/j.ejpb.2017.09.002 · DOI
  11. Chow, 2020, Pharmacokinetics and time-kill study of inhaled antipseudomonal bacteriophage therapy in mice, Antimicrob. Agents Chemother., 65, 10.1128/AAC.01470-20 · DOI
  12. Chuang, 2014, Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease, Gut, 63, 736, 10.1136/gutjnl-2013-304786 · DOI
  13. Dąbrowska, 2019, Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review, Med. Res. Rev., 39, 2000, 10.1002/med.21572 · DOI
  14. Dini, 2012, Novel biopolymer matrices for microencapsulation of phages: enhanced protection against acidity and protease activity, Macromol. Biosci., 12, 1200, 10.1002/mabi.201200109 · DOI
  15. Gómez-Zorrilla, 2015, Prospective observational study of prior rectal colonization status as a predictor for subsequent development of Pseudomonas aeruginosa clinical infections, Antimicrob. Agents Chemother., 59, 5213, 10.1128/AAC.04636-14 · DOI
  16. Handbook of pharmaceutical excipients, (5th ed.) (2006). Pharmaceutical Press, London, United Kingdom.
  17. Heimesaat, 2019, Multidrug-resistant Pseudomonas aeruginosa accelerate intestinal, extra-intestinal, and systemic inflammatory responses in human microbiota-associated mice with subacute ileitis, Front. Immunol., 10, 49, 10.3389/fimmu.2019.00049 · DOI
  18. Hsu, 2020, In situ reprogramming of gut bacteria by oral delivery, Nat. Commun., 11, 5030, 10.1038/s41467-020-18614-2 · DOI
  19. Lawal, 2019, Modified starches as direct compression excipients – effect of physical and chemical modifications on tablet properties: a review, Starch - Stärke., 71, 1800040, 10.1002/star.201800040 · DOI
  20. Ma, 2008, Microencapsulation of bacteriophage felix O1 into chitosan-alginate microspheres for oral delivery, Appl. Environ. Microbiol., 74, 4799, 10.1128/AEM.00246-08 · DOI
  21. Ma, 2012, Enhanced alginate microspheres as means of oral delivery of bacteriophage for reducing Staphylococcus aureus intestinal carriage, Food Hydrocolloids, 26, 434, 10.1016/j.foodhyd.2010.11.017 · DOI
  22. Narang, 2017, Assessment of tablet surface hardness by laser ablation and its correlation with the erosion tendency of core tablets, J. Pharm. Sci., 106, 200, 10.1016/j.xphs.2016.08.008 · DOI
  23. Nasonova, 1970, Use of dysenteric polyvalent bacteriophage in coated tablets for treatment of acute dysentery, Sov. Med., 33, 143
  24. Orlova, 1970, Use of tablet-form polyvalent bacteriophage with acid resistant coating in the treatment of dysentery in children, Vopr. Okhr. Materin. Det., 15, 25
  25. Patel, 2006, Compression physics in the formulation development of tablets, Crit. Rev. Ther. Drug Carrier Syst., 23, 1, 10.1615/CritRevTherDrugCarrierSyst.v23.i1.10 · DOI
  26. Pfeifer, 2010, Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens, Int. J. Med. Microbiol., 300, 371, 10.1016/j.ijmm.2010.04.005 · DOI
  27. Sarker, 2017, Oral application of Escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh, Environ. Microbiol., 19, 237, 10.1111/1462-2920.13574 · DOI
  28. Sayamov, 1963, Treatment and prophylaxis of cholera with bacteriophage, Bull. World Health Organ., 28, 361
  29. Solodovnikov, 1971, Preventive use of dry polyvalent dysentery bacteriophage in preschool institutions. II. Principles of present-day tactics and application schedule of bacteriophage, Zh. Mikrobiol. Epidemiol. Immunobiol., 48, 123
  30. Thoorens, 2014, Microcrystalline cellulose, a direct compression binder in a quality by design environment–a review, Int. J. Pharm., 473, 64, 10.1016/j.ijpharm.2014.06.055 · DOI
  31. Tye, 2005, Evaluation of the effects of tableting speed on the relationships between compaction pressure, tablet tensile strength, and tablet solid fraction, J. Pharm. Sci., 94, 465, 10.1002/jps.20262 · DOI
  32. Vinner, 2018, High precision microfluidic microencapsulation of bacteriophages for enteric delivery, Res. Microbiol., 169, 522, 10.1016/j.resmic.2018.05.011 · DOI
  33. Vinner, 2019, Microencapsulation of Salmonella-specific bacteriophage Felix O1 using spray-drying in a pH-responsive formulation and direct compression tableting of powders into a solid oral dosage form, Pharmaceuticals (Basel), 12, 43, 10.3390/ph12010043 · DOI
  34. Vinner, 2017, Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release, PLoS ONE, 12, e0186239, 10.1371/journal.pone.0186239 · DOI
  35. Zaid, 2020, A comprehensive review on pharmaceutical film coating: past, present, and future, Drug Des. Devel. Ther., 14, 4613, 10.2147/DDDT.S277439 · DOI

Cited by

Sorted by citations

See all 28

Metadata

Authors
Khanal, D., Chang, R. Y. K., Hick, C., Morales, S., & Chan, H.-K.
Affiliations
The University of Sydney (AU)
Corresponding author
Chan, Hak-Kim
ORCID
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2021-11
Volume
609
Pages
121206
ISSN
0378-5173 (ISSN-L)
DOI
10.1016/j.ijpharm.2021.121206
OpenAlex
W3206894640
Cited by
28
References
0
Citations by year
2026: 6 · 2025: 7 · 2024: 6 · 2023: 4 · 2022: 5
FWCI
2.02
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • International Journal of Pharmaceutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Health and Medical Research Council (APP1140617)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
phage therapy, enteric coating, Pseudomonas aeruginosa, gastrointestinal infections, direct compression, tablet formulation, phage stability, multidrug-resistant bacteria, phage cocktail, immunocompromised patients
MeSH terms
Phage Therapy, Administration, Oral, Bacteriophages, Humans, Pseudomonas aeruginosa, Tablets, Tablets, Enteric-Coated

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review